Moleculin Biotech (MBRX) has issued an announcement.
Moleculin Biotech, Inc. has revealed promising additional efficacy results from their Phase 1B/2 clinical trial for Annamycin, used in conjunction with Cytarabine, to treat acute myeloid leukemia. These findings were shared at the prestigious European Hematology Association 2024 Hybrid Congress, and further discussed with top AML experts at a subsequent meeting. This development could signal a notable advancement in the treatment of AML, capturing the interest of investors and stakeholders in the biotech sector.
See more data about MBRX stock on TipRanks’ Stock Analysis page.
